Protagonist Therapeutics, Inc PTGX
We take great care to ensure that the data presented and summarized in this overview for Protagonist Therapeutics, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PTGX
View all-
Farallon Capital Management LLC San Francisco, CA5.86MShares$214 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$210 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$198 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$154 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$116 Million0.01% of portfolio
-
Johnson & Johnson New Brunswick, NJ2.45MShares$89.5 Million35.09% of portfolio
-
Bvf Inc San Francisco, CA1.85MShares$67.6 Million2.64% of portfolio
-
Jefferies Financial Group Inc. New York, NY1.81MShares$66.3 Million0.6% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.73MShares$63.4 Million0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA1.37MShares$50.2 Million0.01% of portfolio
Latest Institutional Activity in PTGX
Top Purchases
Top Sells
About PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Insider Transactions at PTGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2025
|
Sarah A O'Dowd Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,130
+50.0%
|
-
|
|
Jan 02
2025
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,130
+23.05%
|
-
|
|
Jan 02
2025
|
Asif Ali Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,779
+32.26%
|
-
|
|
Jan 02
2025
|
Arturo Md Molina Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,088
+31.95%
|
-
|
|
Jan 02
2025
|
Bryan Giraudo Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,130
+25.32%
|
-
|
|
Jan 02
2025
|
Dinesh V Ph D Patel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
149,800
+21.16%
|
-
|
|
Jan 02
2025
|
Harold E Selick Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,130
+13.41%
|
-
|
|
Jan 02
2025
|
Lewis T Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,130
+50.0%
|
-
|
|
Nov 27
2024
|
Arturo Md Molina Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
26,000
-21.67%
|
$1,144,000
$44.67 P/Share
|
|
Nov 27
2024
|
Arturo Md Molina Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,000
+17.72%
|
$208,000
$8.04 P/Share
|
|
Nov 26
2024
|
Arturo Md Molina Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,529
-10.64%
|
$248,805
$45.6 P/Share
|
|
Nov 26
2024
|
Arturo Md Molina Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,529
+9.62%
|
$44,232
$8.04 P/Share
|
|
Nov 26
2024
|
Dinesh V Ph D Patel President and CEO |
SELL
Open market or private sale
|
Direct |
21,480
-5.0%
|
$988,080
$46.25 P/Share
|
|
Nov 26
2024
|
Suneel Gupta Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,450
+4.83%
|
$365,400
$12.17 P/Share
|
|
Nov 26
2024
|
Suneel Gupta Chief Development Officer |
SELL
Open market or private sale
|
Direct |
19,191
-6.71%
|
$863,595
$45.5 P/Share
|
|
Nov 25
2024
|
Dinesh V Ph D Patel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,727
+0.4%
|
$36,267
$21.58 P/Share
|
|
Nov 25
2024
|
Dinesh V Ph D Patel President and CEO |
SELL
Bona fide gift
|
Direct |
7,000
-1.61%
|
-
|
|
Nov 25
2024
|
Dinesh V Ph D Patel President and CEO |
SELL
Open market or private sale
|
Direct |
78,520
-15.28%
|
$3,611,920
$46.96 P/Share
|
|
Nov 25
2024
|
Suneel Gupta Chief Development Officer |
SELL
Open market or private sale
|
Direct |
103,437
-28.76%
|
$4,758,102
$46.04 P/Share
|
|
Nov 25
2024
|
Suneel Gupta Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
175,000
+16.53%
|
$1,225,000
$7.73 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 248K shares |
|---|---|
| Exercise of conversion of derivative security | 306K shares |
| Payment of exercise price or tax liability | 18.9K shares |
|---|---|
| Bona fide gift | 9K shares |
| Open market or private sale | 423K shares |